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Trends in Psychotropic Dispensing Among
Older Adults with Dementia Living
in Long-Term Care Facilities: 2004e2013
Akshya Vasudev, M.B.B.S., M.D., M.R.C.Psych., Salimah Z. Shariff, B.Math, Ph.D,
Kuan Liu, M.Math, BSc Honours, Amer M. Burhan, MBChB, MScCH, FRCP(C),
Nathan Herrmann, M.D., F.R.C.P(C), Sean Leonard, B.Sc.,
Muhammad Mamdani, M.P.H., M.A., Pharm.D
Objective: Guidelines worldwide have cautioned against the use of antipsychotics as
ﬁrst-line agents to treat neuropsychiatric symptoms of dementia. We aimed to
investigate the changes over time in the dispensing of antipsychotics and other psy-
chotropics among older adults with dementia living in long-term care facilities.
Methods: We used drug claims data from Ontario, Canada, to calculate quarterly
rates of prescription dispensing of six psychotropic drug classes among all elderly
(65 years of age) long-term care residents with dementia from January 1, 2004, to
March 31, 2013. Psychotropic drugs were classiﬁed into the following categories:
atypical and conventional antipsychotics, non-sedative and sedative antidepressants,
anti-epileptics, and benzodiazepines. We used time-series analysis to assess trends
over time. Results: The study sample increased by 21% over the 10-year study period,
from 49,251 patients to 59,785 patients. The majority of patients (within the range of
75%e79%) were dispensed at least one psychotropic medication. At the beginning of
the study period atypical antipsychotics (38%) were the most frequently dispensed
psychotropic, followed by benzodiazepines (28%), non-sedative antidepressants
(27%), sedative antidepressants (17%), anti-epileptics (7%), and conventional anti-
psychotics (3%). Dispensing of anti-epileptics (2% increase) and conventional anti-
psychotics (1% decrease) displayed modest changes over time, but we observed more
pronounced changes in dispensing of benzodiazepines (11% decrease) and atypical
antipsychotics (4% decrease). Concurrently, we observed a substantial growth in the
dispensing of both sedative (15% increase) and non-sedative (9% increase) antide-
pressants. The proportion of patients dispensed two or more psychotropic drug classes
increased from 42% in 2004 to 50% in 2013. Conclusions: Utilization patterns of
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psychotropic drugs in institutionalized patients with dementia have changed over the
past decade. Although their use declined slightly over the study period, atypical an-
tipsychotics continue to be used at a high rate. A decline in the use of benzodiazepines
along with an increased use of sedative and non-sedative antidepressants suggests
that the latter class of drugs is being substituted for the former in the management of
neuropsychiatric symptoms. Psychotropic polypharmacy continues to be highly
prevalent in these patient samples. (Am J Geriatr Psychiatry 2015; 23:1259e1269)
Key Words: Dispensing, antipsychotics, psychotropics, dementia, long-term care
Two out of three elderly long-term care residentssuffer from dementia1,2; of these patients,
approximately 80%3 present with neuropsychiatric
symptoms (NPS) such as anxiety, depression, agita-
tion, psychological distress, psychosis, and/or
insomnia.4 Psychotropic medications are often used
to manage such symptoms.5
In the past decade, numerous drug regulatory
agencies and clinical guidelines have cautioned
against the use of antipsychotics, either conventional
or atypical, to manage NPS; these warnings are based
on ﬁndings of increased risks with these medications
of cerebrovascular events and death.6e12 Nonethe-
less, they continue to be prescribed and dispensed
with varying rates around the world (from 7% to
40%).13e19 The Canadian dementia guidelines have
identiﬁed other classes of psychotropics that may be
considered instead for the management of NPS; these
include antidepressants (sedative and non-sedative),
benzodiazepines, anti-epileptics and cognitive en-
hancers.10 These guidelines, however, as well as
those from other countries, highlight the variable
evidence base for the use of these agents.5,20 It may be
that each class of psychotropic is being differentially
used to target speciﬁc NPS. Though not recom-
mended, physicians may prescribe a combination of
more than one psychotropic drug class in an attempt
to manage the NPS, although the evidence base for
this practice is even more limited.21,22
Although the dispensing rates of psychotropics in
patients with dementia are well documented in the
community setting,23,24 there are limited reports of
their use in the long-term care setting. When
compared with dementia patients in the community
setting, long-term care patients are older, more frail,
and at increased risk of the adverse effects of
psychotropic medications; these include potentially
dangerous drug interactions between co-dispensed
psychotropic medications.
Physicians have become increasingly aware of the
risks associated with the use of antipsychotics in the
elderly and may be shifting their prescribing to other
psychotropics, as single agents or in combination, to
manage the NPS in older patients with dementia in
long-term care facilities. We assessed the dispensing
rate of antipsychotics and other classes of psycho-
tropics in older adults with dementia living in long-
term care facilities from 2004 to 2013.
METHODS
This study was approved by the Sunnybrook
Health Sciences Centre research ethics board in Tor-
onto, Ontario.
Study Design and Setting
We conducted a cross-sectional time-series analysis
in Ontario, Canada. Ontario is the most populous
province of Canada; at the beginning of 2004
approximately 1.3 million Ontarians were 65 years of
age or older. By the end of 2017 this population is
expected to grow to over 1.6 million.25
Data Source and Study Outcomes
We used data from a number of linked healthcare
databases housed at the Institute of Clinical Evalua-
tive Sciences, Ontario, Canada. These databases
included the Registered Persons Database, which
contains demographic information on all Ontario
residents; the Ontario Health Insurance Plan
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database, which contains information on physician
billing claims for inpatient procedures and outpatient
physician visits; the Canadian Institutes of Health
InformationeDischarge Abstract Database, which
contains information about hospitalizations; and the
Ontario Drug Beneﬁts (ODB) database, which con-
tains information on all medications dispensed for
those aged 65 years or older, and identiﬁes whether a
patient resides in a long-term care facility. The ODB
database has been found to have an error rate of less
than 1%.26
Cohort Formation
For the purpose of this study, we divided each
calendar year into four quarters (three-month periods;
quarter 1 [Q1]: January to March, Q2: April to June,
Q3: July to September, Q4: October to December).
Data collection occurred from January 1, 2004,
through March 31, 2013, generating a total of 37
quarters. For each quarter, the study sample
comprised all residents of Ontario aged 66 years and
above living in a long-term care home with a
diagnosis of dementia. Patients were identiﬁed as
having dementia if in the 5 years prior to the start of
the interval they had a hospitalization involving a
diagnosis of dementia (International Classiﬁcation of
Diseases, Tenth Revision [ICD-10] codes: F00, F01,
F02, F03, F05.1, F06.5, F06.6, F06.8, F06.9, G30, G31,
R54) or a physician-documented outpatient diagnosis
for dementia (ICD-9 codes: 290, 331, 797). We selected
a combination of both inpatient and outpatient codes
to maximize the sensitivity of diagnoses; these codes
have been used in previous large-scale database
studies.27e29 To determine long-term care residency
status, we reviewed data from the most recently ﬁlled
prescription in the one year prior to the start of each
quarter. We did not include patients in their ﬁrst year
of prescription-drug coverage (65 years of age) to
allow for a one-year look-back. Figure 1 outlines
additional exclusion criteria and an example of how
each cohort was developed.
Cohort Characteristics
Three quarters were selected a priori to examine
patient characteristics at the beginning (January to
March, 2004), middle (January to March, 2009) and
end (January to March 2013) of the study period. In
addition to demographic characteristics, we used
hospitalization records from the ﬁve years prior to the
start of each quarter to characterize their dementia
diagnosis and generate a Charlson comorbidity in-
dex30 validated for administrative claims databases31
(list of comorbidities presented in Table 1).
Prescription-Level Monitoring
For every quarter, we identiﬁed all prescriptions
for the following psychotropic drug classes: atypical
and conventional antipsychotics, non-sedative and
sedative antidepressants, anti-epileptics, and benzo-
diazepines (speciﬁc drugs are listed in Appendix 1).
We selected these medications as they are frequently
dispensed for the management of the NPS of
dementia. The rate of dispensing of each drug class
was calculated quarterly by summing the number of
patients dispensed a prescription for that drug class
divided by the total number of patients in that
quarter. Similarly, the rate of dispensing combination
psychotropics was assessed by counting the number
of patients who were dispensed with two or more
unique psychotropic drug classes in the quarter being
studied divided by the total number of patients in
that quarter. Medications that did not have universal
provincial coverage throughout the study period, or
where the total count of prescriptions for the sample
was less than 5, were excluded.
Statistical Analysis
To assess trends in the use of psychotropics, data
was analyzed through time-series analysis32 using
exponential smoothing models. Time-series analyses
are well-established methods that use a collection of
techniques for modeling autocorrelations in tempo-
rally sequenced data.32 Schwarz-Bayesian criteria
were used to assess the best model ﬁt. The level,
trend, damping, and seasonality smoothing weights
were determined to optimize the ﬁt of the model. The
statistical signiﬁcance of the smoothing weights was
tested using t tests. Stationarity was determined with
the use of the autocorrelation function and the
augmented Dickey-Fuller test.33 The autocorrelation,
partial autocorrelation, and inverse autocorrelation
functions were further calculated for model param-
eter appropriateness and seasonality. The presence of
white noise was assessed by examining the autocor-
relations at various lag points using the Ljung-Box
c2 statistic.34 Additionally, on a post hoc basis, we
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used exponential smoothing models to forecast the
prescription rate of select psychotropic classes that
exhibited impactful changes in dispensing during the
10-year study period (2004 to 2013); rates were
forecasted to 2017. For assessment of differences in
baseline characteristics across the selected time
points, we conducted the c2 test to examine the
changes in proportion of categorical variables and
Kruskal-Wallis test to examine the changes in me-
dians of continuous variables. SAS software package
for Windows, Version 9.3 (SAS Institute, Inc., Cary,
NC,) was used for all statistical analyses.
RESULTS
Dementia Patients in Ontario Long-Term Care
Homes
The number of patients included in the study
increased by 21% from 49,251 in Q1 2004 to 59,785 in
Q1 2013. The proportion of women reduced from
74% in Q1 2004 (36,204 of 49,251) to 71% (42,739 of
59,785, c2 ¼ 55.74, df ¼ 2, p <0.001). The median age
increased from 85 years to 86 years (Kruskal-Wallis
Test, c2 ¼ 556.24, df ¼ 2, p <0.0001) over the study
period. Alzheimer dementia was the most commonly
diagnosed form of dementia, (98%: 47,903 of 49,251 in
Q1 2004 and 58,237 of 59,785 in Q1 2013, c2 ¼ 13.33,
df ¼ 2, p ¼ 0.0013). The baseline characteristics of
these patients did not appear to change considerably
over time (Table 1).
Dispensing Changes
The proportion of patients dispensed each psy-
chotropic drug class from January 1, 2004, to March
31, 2013, is presented in Figure 2. Further statistical
details of all model results presented herein are
available in Table 2. Among the classes of psycho-
tropics included in the analyses, the proportion of
patients on anti-epileptics (2 percentage point
FIGURE 1. Illustration of development of one sub-cohort, Quarter 1 2004.
Number of paƟents on Jan 1st 2004 who had demenƟa diagnosis within the previous 5 years. 
n= 282,134
Number Excluded, n= 232,883
PaƟents with missing age or sex idenƟficaƟon, n=16
PaƟents with death on or before the beginning of each Ɵme interval, n=111,271
PaƟents with a non-Ontario residence at the beginning of each Ɵme interval, n= 1,196
PaƟents with age < 66 at the beginning of each Ɵme interval, n=33,859
PaƟents with no ODB drug prescripƟon in the previous 1 year to the beginning of each interval, 
n=5,419
PaƟents not living in a long-term care (LTC) facility as idenƟfied by their most recent ODB claim, 
n=81,122
Number of paƟents included in final sub-cohort, 
n= 49,251
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increase: 3,669 of 49,251 ¼ 7% in Q1 2004 and 5,450 of
59,785 ¼ 9% in Q1 2013) and conventional antipsy-
chotics (1 percentage point decrease: 1,784 of
49,251 ¼ 3% in Q1 2004 and 1,247 of 59,785 ¼ 2% in
Q1 2013) demonstrated modest changes over the
study period. We found a larger reduction in the
proportion of the patients dispensed benzodiaze-
pines (11 percentage point decrease: 13,835 of
49,251 ¼ 28% in Q1 2004 to 10,103 of 59,785 ¼ 17% in
Q1 2013) and atypical antipsychotics (4 percentage
point decrease: 18,700 of 49,251 ¼ 38% in Q1 2004 to
20,082 of 59,785 ¼ 34% in Q1 2013). There was a
concurrent large change in proportion of patients
dispensed a sedative antidepressant (15 percentage
point increase: 8,245 of 49,251 ¼ 16% in Q1 2004
and 18,277 of 59,785 ¼ 31% in Q1 2013), as well as
non-sedative antidepressants (9 percentage point in-
crease: 13,053 of 49,251 ¼ 27% in Q1 2004 and 21,512
of 59,785 ¼ 36% in Q1 2013).
Overall, the proportion of patients dispensed any
psychotropic drug increased from 75% in Q1 2004
(36,825 of 49,251) to 79% in Q1 2013 (47,330 of
TABLE 1. Clinical and Demographic Characteristics of the Study Sample
January 1, 2004 January 1, 2009 January 1, 2013
Total
N [ 49,251 %
Total
N [ 56,723 %
Total
N [ 59,785 %
Demographics
Age (years)
Mean (SD) 84.41 (7.35) 84.92 (7.24) 85.36 (7.39)
Median (IQR) 85 (80e90) 85 (80e90) 86 (81e91)
66e75.9 6,127 12.44 6,154 10.85 6,463 10.81
76e85.9 20,433 41.49 22,525 39.71 21,456 35.89
86e95.9 19,850 40.30 24,567 43.31 27,751 46.42
96þ 2,841 5.77 3,477 6.13 4,115 6.88
Sex e Female, N 36,204 73.51 41,157 72.56 42,739 71.49
Diagnosis of type of dementia, N
Alzheimer dementia 47,903 97.26 55,350 97.58 58,327 97.56
Vascular dementia 1,621 3.29 1,454 2.56 1,366 2.28
Other dementias 8,020 16.28 4,151 7.32 3,890 6.51
Unspeciﬁed dementias 5,627 11.43 11,829 20.85 14,580 24.39
Organic brain syndrome 305 0.62 257 0.45 154 0.26
Delirium superimposed on dementia 1,435 2.91 1,949 3.44 3,201 5.35
Comorbidities (Charlson Comorbidity Index Categorizations), N
AMI 3,003 6.10 2,831 4.99 2,776 4.64
CHF 5,326 10.81 5,061 8.92 5,151 8.62
PVD 1,750 3.55 1,479 2.61 1,406 2.35
CVD 5,506 11.18 4,402 7.76 3,996 6.68
COPD / Other respiratory disease 4,780 9.71 3,963 6.99 4,119 6.89
Rheumatologic disease 668 1.36 491 0.87 528 0.88
Digestive ulcer 682 1.38 641 1.13 693 1.16
Mild liver disease 366 0.74 242 0.43 272 0.45
Diabetes 5,459 11.08 3,994 7.04 3,777 6.32
Diabetes with chronic complications 1,018 2.07 5,406 9.53 8,061 13.48
Hemi or paraplegia 2,106 4.28 1,775 3.13 1,680 2.81
Renal disease 2,069 4.20 3,348 5.90 3,273 5.47
Primary cancer 991 2.01 1,278 2.25 1,406 2.35
Moderate / Severe liver disease 83 0.17 111 0.20 119 0.20
Metastatic cancer 334 0.68 337 0.59 407 0.68
HIV infection 5 <0.01 5 <0.01 5 <0.01
Charlson Index (Weighted Sum)
Mean (SD) 1.69 (1.09) 1.62 (1.02) 1.61 (0.99)
Median (IQR) 1 (1e2) 1 (1e2) 1 (1e2)
1 30,074 61.06 35,940 63.36 37,018 61.92
2 10,188 20.69 11,756 20.73 13,369 22.36
3 5,124 10.40 5,421 9.56 5,721 9.57
4þ 3,865 7.85 3,606 6.36 3,677 6.15
Notes: AMI: acute myocardial infarction; CHF: congestive heart failure; CVD: cerebrovascular disease; COPD: chronic obstructive pul-
monary disease; HIV: human immunodeﬁciency virus; IQR: interquartile range; PVD: peripheral vascular disease; SD: standard deviation.
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59,785). Over the same period, the proportion of
study patients on two or more different classes of
psychotropics increased from 42% (21,019 of 49,251)
to 50% (29,928 of 59,785) (Fig. 3).
Projection of Dispensing Proportions
Based on the three psychotropic classes that
exhibited the largest changes during the past decade
(2004e2013), over the next four years (2014e2017)
the following projections were made: The proportion
of patients dispensed atypical antipsychotics may
decrease from 34% to 31% and benzodiazepine use
may decrease from 17% to 8% of patients while the
proportion dispensed sedative antidepressant is ex-
pected to continue increasing from 32% to 36% of
patients (Fig. 4).
DISCUSSION
This study provides an analysis of trends over time
(2004e2013) in the dispensing of six classes of psy-
chotropics for the treatment of NPS among frail,
older patients with dementia residing in long-term
care facilities in Ontario, Canada. Over the past
decade the overall psychotropic use has remained
stable, with nearly three-quarters of all patients
dispensed at least one medication. We observed a
marginal but statistically signiﬁcant decline in the
proportion of patients dispensed antipsychotics
(atypical and conventional) and anti-epileptics, and a
more dramatic decline in proportion of patients on
benzodiazepines was observed. Conversely, use of
sedative and non-sedative antidepressants increased
markedly. We also observed an overall increase in
psychotropic combination therapy.
Interpretation
Among other ﬁndings, we saw a relatively high and
steady usage of antipsychotics contrasting with a
declining use of benzodiazepines; this pattern has been
shown in previous studies. Those studies, however, did
not examine psychotropic drug use in patients living in
long-term care homes.6,19,35,36 The ongoing and pro-
jected high dispensing of atypical antipsychotics is of
concern in the context of multiple warnings around
cerebrovascular events and death associated with these
FIGURE 2. Proportion of patients (percentage) dispensed six classes of psychotropics from January 1, 2004 to March 31, 2013
among patients with dementia in long-term care facilities in Ontario, Canada.
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agents.6e12 On the other hand, the declining use of
benzodiazepines is reassuring, as this would have
likely resulted in fewer incidents of falls, fractures, and
subsequent hospital admissions over the past decade.37
This study highlights an increased use of non-
sedative antidepressants. This trend needs to be
viewed in the context of the Canadian Consensus
Conference on the Diagnosis and Treatment of
TABLE 2. Statistical Details of Best-Fitting Smoothing Models
Drug Class Best Fitting Model
t Test
Statistic
Degrees
of
Freedom
Mean
Square
Error
R2
Value
Schwarz
Bayesian
Information
Criterion
(BIC) p Value
Sedative
antidepressants
Winter Additive 7.9802 34 0.03259 0.998 115.84848 <0.001
Cognitive
enhancers
Winter Additive 9.1833 34 0.02068 0.999 132.67327 <0.001
Non-sedative antidepressants Linear (Holt)
Exponential Smoothing
5.4507 35 0.02886 0.998 123.95571 <0.001
Benzodiazepines Linear (Holt)
Exponential Smoothing
6.3588 35 0.04548 0.995 107.12739 <0.001
Atypical antipsychotics Log Double (Brown)
Exponential Smoothing
10.3349 35 0.07874 0.966 90.42799 <0.001
Conventional antipsychotics Log Linear (Holt)
Exponential Smoothing
5.6427 35 0.0054253 0.964 185.79540 <0.001
Anti-epileptic drugs Log Double (Brown)
Exponential Smoothing
8.2677 35 0.06551 0.881 97.23334 <0.001
Any one class of psychotropic Winter Additive 4.3938 34 0.03247 0.987 115.98170 0.001
Two or more different classes
of psychotropics
Winter Additive 7.0046 34 0.07041 0.989 87.34621 <0.001
Note: p values test the null hypothesis that the level (intercept) smoothing weight equals 0.
FIGURE 3. Proportion of patients on one or more classes of psychotropics among patients with dementia living in long-term care
facilities in Ontario, Canada, from 2004 to 2013.
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Dementia (CCCDTD),12 which acknowledges that
the use of antidepressants for managing affective
disturbances associated with dementia are an option,
but not a ﬁrm recommendation. These recommen-
dations were partly based on a recent noneindustry-
sponsored large sample study, which failed to ﬁnd
any difference in the effects of sertraline, mirtaza-
pine, or placebo in a randomized controlled
setting.38 Nevertheless, a more recent study focusing
on the management of agitation in the context of
dementia found some beneﬁts with citalopram, a
non-sedative antidepressant,39 although there were
adverse effects on cognition and the cardiovascular
system.
We also found that long-term care residents with
dementia are increasingly being dispensed sedative
antidepressants, which include medications such as
trazodone, mirtazapine, and tricyclic antidepressants.
We suspect that the increased use of sedative anti-
depressants is for the promotion of sedation, the
treatment of comorbid depression, or to manage the
agitation or aggression associated with dementia.
Because of the large sample-based nature of this
study we are unable to conﬁrm any of the above
reasons for this usage. Although not speciﬁcally
tested, however, the converse increase in antide-
pressant dispensing with declines in benzodiazepine
dispensing suggests that prescribers may be
substituting benzodiazepines with antidepressants
in an attempt to manage NPS. The ongoing and
projected increase in the usage of sedative antide-
pressants is of possible concern as the safety and
effectiveness of these agents is based only on small-
scale studies.40e42 For instance, the administration
FIGURE 4. Actual and projected use of [A] sedative antidepressants, [B] atypical antipsychotics, and [C] benzodiazepines among
patients with dementia living in long-term care facilities in Ontario, Canada. from 2004 to 2013.
Notes: The number of actual prescriptions from Q1 2004 to Q1 2013 are depicted by solid blue squares; the predicted prescriptions
are depicted by dotted red lines; 95% conﬁdence intervals around the projected prescriptions beyond Q1 2013 are presented as red dashed
lines/error bars. The vertical blue line denotes the beginning of the period of projected data.
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of mirtazapine for the treatment of depressive
symptoms in outpatients with dementia led to
reports of excessive drowsiness and sedation in 44%
of patients.24 Such symptoms could increase the risk
of falls, injuries, fractures, and mortality. Therefore,
the use of sedative antidepressants for the NPS of
dementia needs to be further investigated.
One of the other recommendations of the CCCDTD
was to reduce reliance on the usage of anti-epileptics,
particularly valproate, as it has been associated with
signiﬁcant toxicity, accelerated brain volume loss,
greater cognitive impairment, and a similar risk of
mortality as that previously found with antipsy-
chotics.10 The ongoing use of such agents is therefore
of some concern.
We also examined the extent of the dispensing of
combination psychotropic medications; such usage
may further increase the risk of cognitive impair-
ment, orthostatic hypotension, falls, and skeletal
fractures.43 In order to compare psychotropic pre-
scription rates we divided the patients into two
groups: those on one, and those on two or more
classes of agents. We did not attempt to categorize
whether certain psychotropic combination pre-
scriptions were pharmacologically appropriate or
not, as there is an inadequate evidence base for
taking this approach.44 We do, however, recognize
that physicians caring for patients with dementia in
long-term care settings are often faced with the
dilemma of balancing the use of psychotropic com-
bination therapy with its associated risks. These
physicians must also take into account the need to
reduce the anxiety in staff and other residents
caused by patients’ calling out, agitation, hallucina-
tions, and other NPS associated with dementia.45
Fortunately, it is possible to reduce potentially
inappropriate combination therapy through
concerted multidisciplinary and frequent medication
reviews.46
In light of the limitations posed by pharmacolog-
ical treatments, nonpharmacological interventions
using music or environmental manipulation may
provide alternatives for the management of NPS.
There is some evidence that such interventions can be
of beneﬁt if tailored to the individual patient, and if
healthcare providers are given adequate support to
offer such treatments.47 High-quality large-scale
studies for assessing the efﬁcacy of such therapies
have yet to be performed.48
Study Limitations
There are several limitations to the present study.
First, this study was retrospective in nature and
hence suffers from inherent biases associated with
such a design. Second, healthcare databases do not
code dementias using the more stringent standard-
ized diagnostic criteria for characterizing the type or
severity of dementia as suggested by the National
Institute on Aging/Alzheimer’s Association Diag-
nostic Guidelines for Alzheimer’s Disease; such
diagnoses are typically used for characterizing
patients in prospective randomized controlled trials.
Our approach of using either an outpatient, or an
inpatient physician coding, however, would offer
increased sensitivity, without compromising on
speciﬁcity of diagnosis.27e29 Third, we were unable
to accurately capture the dispensing of cognitive en-
hancers as they were not universally covered under
the drug compensation plan in Ontario (ODB) during
the study period. Fourth, we did not characterize
the usage of individual psychotropic within each
drug class, as this would have led to an inordinately
large amount of data, making it difﬁcult to interpret
the results. Fifth, additional clinical information is
required to better characterize patients; this better
understanding of a patient’s needs will help to
identify appropriate drug use, and to develop a
structured approach for dealing with polymedicated
patients. Finally, the extrapolated prediction-model-
eprojected psychotropic usages are based on as-
sumptions inherent to the model used, and as such
do not account for outside variables that may inﬂu-
ence future trends such as changes in formulary
coverage, introduction of new medications, or
changes in practice guidelines.
Conclusions and Implications
This study outlines current trends in the
dispensing of various classes of psychotropics for the
treatment of NPS in patients with dementia residing
in long-term care facilities in Ontario, Canada. The
results suggest a high prevalence of sedative antide-
pressant usage with a concomitant decline in the
usage of antipsychotics and benzodiazepines, sug-
gesting that the former have supplanted the latter in
their role as sedative agents. The increase in psy-
chotropic polypharmacy suggests an ongoing
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reliance on psychotropic usage in the management of
patients with dementia in long-term care where
provisions of nonpharmacological therapies are
likely inadequate. In the absence of ﬁrm evidence
from large-scale randomized controlled trials
regarding the efﬁcacy and safety of various psycho-
tropics (including sedative antidepressants) for the
treatment of NPS in the context of frail elderly with
dementia in long-term care, this report represents an
important contribution to research on a major public
health concern.
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